Author: Lee, Yong-ho; Kim, Jae Hyeon; Kim, So Ra; Jin, Heung Yong; Rhee, Eun-Jung; Cho, Young Min; Lee, Byung-Wan
Title: Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness Document date: 2016_11_8
ID: 4fwp1dnl_17
Snippet: After 24 weeks of treatment with lobeglitazone, the mean CAP value significantly decreased by 5.0%, from 313.4 ± 30.9 dB/m to 297.8 ± 39.1 dB/m (P = 0.016); the mean HbA1C value was reduced by 11.1%, from 7.4% ± 0.4% (57.9 ± 4.9 mM/M) to 6.6% ± 0.4% (48.5 ± 4.8 mM/M) (P < 0.001) ( Fig. 2A and 2B ). Among the 43 participants, 28 (65.1%) showed significant decreases in their CAP values after the 24-week lobeglitazone treatment, compared with .....
Document: After 24 weeks of treatment with lobeglitazone, the mean CAP value significantly decreased by 5.0%, from 313.4 ± 30.9 dB/m to 297.8 ± 39.1 dB/m (P = 0.016); the mean HbA1C value was reduced by 11.1%, from 7.4% ± 0.4% (57.9 ± 4.9 mM/M) to 6.6% ± 0.4% (48.5 ± 4.8 mM/M) (P < 0.001) ( Fig. 2A and 2B ). Among the 43 participants, 28 (65.1%) showed significant decreases in their CAP values after the 24-week lobeglitazone treatment, compared with their CAP values at baseline; therefore, the select 28 were defined as lobeglitazone responders.
Search related documents:
Co phrase search for related documents- CAP value and lobeglitazone treatment: 1, 2, 3, 4
- CAP value and mean CAP value: 1, 2, 3
- HbA1C value and mean HbA1C value: 1, 2, 3, 4, 5
- HbA1C value and significant decrease: 1, 2
- lobeglitazone responder and mean CAP value: 1
- lobeglitazone treatment and mean CAP value: 1
Co phrase search for related documents, hyperlinks ordered by date